Generic Name and Formulations:
Florbetapir F 18 [500-1900MBq/mL (13.5-51mCi/mL) at End of Synthesis (EOS)]; soln for IV inj.
Lilly, Eli and Company
Indications for AMYVID:
For PET imaging of the brain to estimate β-amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. As an adjunct to other diagnostic evaluations. Limitations of use: a positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder. Safety and efficacy not established for predicting development of dementia or other neurologic conditions; or for monitoring responses to therapies.
See full labeling. Give 370MBq (10mCi), max 50μg mass dose, as a single IV bolus dose in a total volume of ≤10mL, then follow with a sterile NaCl 0.9% IV flush. Starting 30–50mins after IV inj, acquire a 10-min PET image. The radiation absorbed dose from 370MBq (10mCi) dose is 7mSv.
Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk of image misinterpretation and other errors. Perform image interpretation independently of patient's clinical information. Pregnancy (Cat.C.); assess status in females of reproductive potential prior to therapy. Nursing mothers: not recommended, or temporarily interrupt for 24hrs after Amyvid exposure.
Radioactive diagnostic agent.
Headache, musculoskeletal pain, increased BP, nausea, fatigue, inj site reactions.
Multi-dose vials (10mL, 30mL, 50mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders